Cargando…

Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma

LAG-3 is one of the common tumor immune checkpoints. LAG-3 can inhibit the activation and proliferation of T cells, and can also suppress immunity by regulating other immune-related cell functions. FGL1 was recently discovered to be the main ligand of immune checkpoint LAG-3 and play a critical role...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Qing, Lin, Hao-Ming, Zhu, Ke, Cao, Yi, Xu, Xiao-Lin, Zhou, Zi-Yu, Xu, Lei-bo, Liu, Chao, Zhang, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901582/ https://www.ncbi.nlm.nih.gov/pubmed/35273912 http://dx.doi.org/10.3389/fonc.2022.810269

Ejemplares similares

Targeting FGL2 in glioma immunosuppression and malignant progression
por: Ma, Xiaoyu, et al.
Publicado: (2022)

Nomograms Incorporating the CNLC Staging System Predict the Outcome of Hepatocellular Carcinoma After Curative Resection
por: Liao, Rui, et al.
Publicado: (2022)

Model to Predict Overall Survival in Patients With Hepatocellular Carcinoma After Curative Hepatectomy
por: Zhang, Li-xiang, et al.
Publicado: (2021)

Preoperative Prognostic Nutritional Index and Neutrophil-to-Lymphocyte Ratio Predict Survival Outcomes of Patients With Hepatocellular Carcinoma After Curative Resection
por: Qu, Zhen, et al.
Publicado: (2022)

Positive Phospho-Focal Adhesion Kinase in Gastric Cancer Associates With Poor Prognosis After Curative Resection
por: Peng, Ke, et al.
Publicado: (2022)

Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection
por: Xu, Yuyan, et al.
Publicado: (2023)

FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma
por: Lv, Zheng, et al.
Publicado: (2021)

Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
por: Shi, An-Ping, et al.
Publicado: (2022)

Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study
por: Liu, Zhi-Peng, et al.
Publicado: (2022)

Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Huang, Xiaozhun, et al.
Publicado: (2021)

Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis
por: Liu, Kai-Xuan, et al.
Publicado: (2021)

Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1–FGL1–MYH9 axis
por: Tang, Xi-Yang, et al.
Publicado: (2022)

Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
por: Qian, Wenjing, et al.
Publicado: (2021)

Prognostic Stratification Based on a Novel Nomogram for Solitary Large Hepatocellular Carcinoma After Curative Resection
por: Zhuang, Hongkai, et al.
Publicado: (2020)

Risk Factors and Outcomes of Early Relapse After Curative Resection of Intrahepatic Cholangiocarcinoma
por: Yang, Hua, et al.
Publicado: (2019)

Hypomethylation of long interspersed nuclear element-1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma
por: Gao, Xu-dong, et al.
Publicado: (2014)

Overexpression of GINS4 Is Associated With Tumor Progression and Poor Survival in Hepatocellular Carcinoma
por: Zhang, Ziying, et al.
Publicado: (2021)

Immunohistochemical Signature Add Prognostic Value in Patients With Early and Intermediate Hepatocellular Carcinoma Underwent Curative Liver Resection
por: Bai, Yannan, et al.
Publicado: (2021)

A sample model established by S-index predicting overall survival after curative resection of primary hepatocellular carcinoma
por: Chen, Lei, et al.
Publicado: (2019)

Sarcopenia and visceral adiposity predict poor overall survival in hepatocellular carcinoma patients after curative hepatic resection
por: Jang, Hee Yoon, et al.
Publicado: (2021)

Immune Checkpoint Blockade in Chinese Patients With Hepatocellular Carcinoma: Characteristics and Particularity
por: Wu, Yaoqiang, et al.
Publicado: (2022)

Development and validation of prognostic dynamic nomograms for hepatitis B Virus-related hepatocellular carcinoma with microvascular invasion after curative resection
por: Bai, Shilei, et al.
Publicado: (2023)

Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma()
por: Dai, Xiaomeng, et al.
Publicado: (2017)

Predicting Disease-Specific Survival for Patients With Primary Cholangiocarcinoma Undergoing Curative Resection by Using a Decision Tree Model
por: Quan, Bing, et al.
Publicado: (2022)

Impact of perioperative blood transfusion on long-term survival in patients with different stages of perihilar cholangiocarcinoma treated with curative resection: A multicentre propensity score matching study
por: Liu, Zhi-Peng, et al.
Publicado: (2022)

ATAD2 as a Poor Prognostic Marker for Hepatocellular Carcinoma after Curative Resection
por: Hwang, Hye Won, et al.
Publicado: (2015)

Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy
por: Rolles, Benjamin, et al.
Publicado: (2021)

High RPS11 level in hepatocellular carcinoma associates with poor prognosis after curative resection
por: Zhou, Chenhao, et al.
Publicado: (2020)

Folate receptor-positive circulating tumor cells predict survival and recurrence patterns in patients undergoing resection for pancreatic cancer
por: Cheng, Hao, et al.
Publicado: (2022)

Elevated preoperative peripheral blood monocyte count predicts poor prognosis for hepatocellular carcinoma after curative resection
por: Shen, Shun-Li, et al.
Publicado: (2014)

High S100A9(+) cell density predicts a poor prognosis in hepatocellular carcinoma patients after curative resection
por: Liao, Jing, et al.
Publicado: (2021)

TMPRSS4 facilitates epithelial-mesenchymal transition of hepatocellular carcinoma and is a predictive marker for poor prognosis of patients after curative resection
por: Wang, Cheng-Hao, et al.
Publicado: (2015)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Comparison of stereotactic body radiation therapy with hepatic resection and radiofrequency ablation as initial treatment in patients with early-stage hepatocellular carcinoma
por: Yang, Zi-liang, et al.
Publicado: (2022)

The Role of Preoperative Dynamic Contrast-enhanced 3.0-T MR Imaging in Predicting Early Recurrence in Patients With Early-Stage Hepatocellular Carcinomas After Curative Resection
por: Zhang, Linqi, et al.
Publicado: (2019)

The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
por: Huang, Jiacheng, et al.
Publicado: (2021)

Importance of Microvascular Invasion Risk and Tumor Size on Recurrence and Survival of Hepatocellular Carcinoma After Anatomical Resection and Non-anatomical Resection
por: Hu, Haoyu, et al.
Publicado: (2021)

Cholecystectomy is associated with higher risk of early recurrence and poorer survival after curative resection for early stage hepatocellular carcinoma
por: Li, Tao, et al.
Publicado: (2016)

Fgl2: link between hepatitis B and SARS?
por: Robertson, Morag
Publicado: (2003)

Immune Checkpoint Inhibitor-Based Systemic Therapy Shows Remarkable Curative Effect in a Hepatocellular Carcinoma Patient With Intractable Postoperative Recurrence and Metastases: A Case Report and Literature Review
por: He, Xing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oe8lb6qjnlg1gqbthhffms4pbv